GlassScriptPhysician profile
Margaret A Cusack
NPI 1902929987
$5,433.49
in general payments reported to CMS, 2019-2025
45 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $425 · 2022: $1,880 · 2023: $656 · 2024: $1,235 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,129.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $1,453.75 | 2022 | |
| Abbvie INC. | $611.20 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $263.60 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $231.68 | 2024-2025 | Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $218.39 | 2021-2025 | Trintellix |
| Bausch Health US, LLC | $200.05 | 2021-2022 | |
| Novo Nordisk INC | $187.82 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $176.77 | 2024 | Spravato |
| Glaxosmithkline, LLC. | $175.30 | 2021-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $157.76 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $151.98 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Indivior INC. | $136.27 | 2024-2025 | Sublocade, Perseris |
| Axsome Therapeutics, INC. | $133.61 | 2023-2025 | Auvelity |
| Lilly USA, LLC | $128.37 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Neurocrine Biosciences, INC. | $121.99 | 2024 | Ingrezza |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $115.22 | 2024 | Brixadi |
| Gilead Sciences, INC. | $107.70 | 2023-2025 | |
| Dexcom, INC. | $70.42 | 2024-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $63.15 | 2021-2025 | Airsupra, Breztri |
| Antares Pharma, INC. | $56.22 | 2021-2025 | Xyosted |
| Merck Sharp & Dohme LLC | $52.41 | 2021-2023 | Belsomra |
| Abbott Laboratories | $47.92 | 2025 | Freestyle Libre 3 |
| Supernus Pharmaceuticals, INC. | $43.56 | 2021-2024 | Qelbree |
| Lundbeck LLC | $43.41 | 2025 | Rexulti |
| Eisai INC. | $42.83 | 2021 | |
| Almatica Pharma LLC | $37.06 | 2024 | Loreev Xr |
| Collegium Pharmaceutical, INC. | $36.22 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $35.55 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.26 | 2025 | Xifaxan |
| Vanda Pharmaceuticals INC. | $30.91 | 2025 | Fanapt |
| Biogen, INC. | $29.42 | 2024 | Skyclarys |
| Currax Pharmaceuticals LLC | $27.52 | 2024 | Contrave, Onzetra Xsail |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.88 | 2023 | Jardiance |
| Alkermes, INC. | $21.79 | 2025 | Aristada, Lybalvi |
| Astellas Pharma US INC | $20.17 | 2025 | Veozah |
| Tris Pharma INC | $20.07 | 2024 | Dyanavel Xr |
| Corium, LLC | $19.48 | 2024 | Azstarys |
| Medicure Pharma INC. | $17.18 | 2023 | Zypitamag |
| Noven Therapeutics, LLC | $15.57 | 2024 | Xelstrym |
| Jazz Pharmaceuticals INC. | $15.37 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.41 | 2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $13.34 | 2021 | |
| Exeltis, USA INC. | $13.26 | 2023 | Slynd |
| Arbor Pharmaceuticals, INC. | $12.62 | 2021 | |
| Genentech USA, INC. | $7.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Cusack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.